Thursday, November 19, 2026Thu, Nov 19

Moon: waxing gibbous, 72% litAurora: quiet

Español

Space, Earth and the natural world, explained.

Extra SORLA Protein Cuts Tau Tangles and Brain Shrinkage in Mice

Mice with extra SORLA protein had fewer tau tangles and less brain shrinkage, Sanford Burnham Prebys researchers report in Science Advances.

Doctor analyzing brain scans on a tablet in a clinical setting.
Photo: Vitaly Gariev / Pexels

Raising the level of a brain protein called SORLA reduced tau tangles, protected the connections between nerve cells and limited brain shrinkage in mice bred to develop Alzheimer’s-like damage. Researchers at Sanford Burnham Prebys reported the result in Science Advances. Mice that could not make SORLA at all fared worse.

Tau is a normal protein that helps stabilize microtubules, the tiny internal supports of neurons. In Alzheimer’s and related diseases, called tauopathies, tau turns abnormal and sticks together into tangles that disrupt nerve cells and are associated with cognitive decline and cell death.

How the team tested SORLA

SORLA is short for sorting-related receptor with A-type repeats. Earlier work from several labs had shown that it limits amyloid-beta, the protein that builds up into plaques. Timothy Huang, an assistant professor at Sanford Burnham Prebys, said little was known about whether SORLA also affected tau.

To find out, the team bred mice engineered to make extra human SORLA with mice that develop tau tangles, brain atrophy and cognitive impairments. Extra SORLA reduced hyperphosphorylation, a change in which too many phosphate groups attach to tau and push it toward forming tangles. It also limited the ability of misfolded tau to act as a “seed” that pulls other tau proteins into clumps. Synapses, the junctions where neurons communicate, were better preserved, as was synaptic plasticity, the ability to strengthen or change those connections.

“We found there was less brain atrophy and less tau accumulation,” said Huijie Huang, lead author of the study.

The researchers then tested the reverse. SORLA is made from instructions in a gene called Sorl1, and some people carry mutations that interfere with it. Mice engineered to lack Sorl1, and so unable to make SORLA, showed more severe tau-related damage.

What single-cell data showed

The team measured protein levels and gene activity in individual brain cells and mapped where RNA and proteins sit within tissue. Higher SORLA prevented harmful changes in protein production at synapses and reduced abnormal gene activity in glial cells, which support and protect neurons.

When SORLA was absent, a member of the plexin-B family of receptors became more active. These receptors help cells respond to signals from their surroundings. Drugs that target this receptor class already exist, and Timothy Huang said they might be repurposed to calm overactive glial cells in tauopathies.

How sure is this?

The work was done in mice, and the sources state that more research is needed to learn how these mechanisms operate in humans. It was published in a journal (Science Advances, 2026, volume 12, issue 29, DOI 10.1126/sciadv.aed6825), and it was supported by the National Institutes of Health, the National Cancer Institute and the National Institute on Aging. No drug has been tested in people on the basis of this result. Whether plexin-B drugs would help in tau-related dementia is a proposal, not a finding.

What comes next

The team plans to study how individual brain cell types respond when SORLA rises or falls. One approach is to transplant human neurons or glial cells into mouse brains, so that different SORLA mutations can be examined in human cells inside a diseased brain. “Mouse cells and human cells are different,” Timothy Huang said.

The researchers hope the work will point to treatments that either boost SORLA activity or repurpose existing drugs. For background on how a gene such as Sorl1 leads to a finished protein, see how genes are turned into proteins.

Source: ScienceDaily

Site editor: Nikita Sheikin